Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

Science Translational Medicine

Volumn 6, Issue 252, 2014, Pages

  Wan, Xinhai ^a   Corn, Paul G ^a   Yang, Jun ^a   Palanisamy, Nallasivam ^b   Starbuck, Michael W ^a,c   Efstathiou, Eleni ^a,d   Li Ning Tapia, Elsa M ^a   Zurita, Amado J ^a   Aparicio, Ana ^a   Ravoori, Murali K ^a   Vazquez, Elba S ^e   Robinson, Dan R ^b   Wu, Yi Mi ^b   Cao, Xuhong ^b   Iyer, Matthew K ^b   McKeehan, Wallace ^f   Kundra, Vikas ^a   Wang, Fen ^f   Troncoso, Patricia ^a   Chinnaiyan, Arul M ^b   Logothetis, Christopher J ^a   Navone, Nora M ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Bone Disease Program of Texas   (United States)

^d UNIVERSITY OF ATHENS   (Greece)

^e Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^f TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOVITINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROSTATE SPECIFIC ANTIGEN; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE QUALITY; BONE SCINTISCANNING; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL INTERACTION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPH NODE; LYMPH NODE SIZE; MOLECULAR INTERACTION; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOBLAST; POSITIVE FEEDBACK; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; APOPTOSIS; BONE; BONE NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUINOLONES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907289340     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009332     Document Type: Article

References (36)

1. B. I. Carlin, G. L. Andriole, The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88, 2989-2994 (2000).
2. R. D. Loberg, C. J. Logothetis, E. T. Keller, K. J. Pienta, Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J. Clin. Oncol. 23, 8232-8241 (2005).
3. N. Turner, R. Grose, Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 10, 116-129 (2010).
4. P. G. Corn, F. Wang, W. McKeehen, N. Navone, Targeting fibroblast growth factor pathways in prostate cancer. Clin. Cancer Res. 19, 5856-5866 (2013).
5. C. J. Powers, S. W. McLeskey, A. Wellstein, Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 7, 165-197 (2000).
6. D. M. Ornitz, FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22, 108-112 (2000).
7. N. Gotoh, Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 99, 1319-1325 (2008).
8. W. L. McKeehan, F. Wang, M. Kan, The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog. Nucleic Acid Res. Mol. Biol. 59, 135-176 (1998).
9. V. D. Acevedo, R. D. Gangula, K. W. Freeman, R. Li, Y. Zhang, F. Wang, G. E. Ayala, L. E. Peterson, M. Ittmann, D. M. Spencer, Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 12, 559-571 (2007).
10. S. Memarzadeh, L. Xin, D. J. Mulholland, A. Mansukhani, H. Wu, M. A. Teitell, O. N. Witte, Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12, 572-585 (2007).
11. Y. Zhang, J. Zhang, Y. Lin, Y. Lan, C. Lin, J. W. Xuan, M. M. Shen, W. L. McKeehan, N. M. Greenberg, F. Wang, Role of epithelial cell fibroblast growth factor receptor substrate 2α in prostate development, regeneration and tumorigenesis. Development 135, 775-784 (2008).
12. M. P. Valta, J. Tuomela, A. Bjartell, E. Valve, H. K. Väänänen, P. Härkönen, FGF-8 is involved in bone metastasis of prostate cancer. Int. J. Cancer 123, 22-31 (2008).
13. Z. G. Li, P. Mathew, J. Yang, M. W. Starbuck, A. J. Zurita, J. Liu, C. Sikes, A. S. Multani, E. Efstathiou, A. Lopez, J. Wang, T. V. Fanning, V. G. Prieto, V. Kundra, E. S. Vazquez, P. Troncoso, A. K. Raymond, C. J. Logothetis, S. H. Lin, S. Maity, N. M. Navone, Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 118, 2697-2710 (2008).
14. J. Yang, K. Fizazi, S. Peleg, C. R. Sikes, A. K. Raymond, N. Jamal, M. Hu, M. Olive, L. A. Martinez, C. G. Wood, C. J. Logothetis, G. Karsenty, N. M. Navone, Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 61, 5652-5659 (2001).
15. S. Roychowdhury, M. K. Iyer, D. R. Robinson, R. J. Lonigro, Y. M. Wu, X. Cao, S. Kalyana-Sundaram, L. Sam, O. A. Balbin, M. J. Quist, T. Barrette, J. Everett, J. Siddiqui, L. P. Kunju, N. Navone, J. C. Araujo, P. Troncoso, C. J. Logothetis, J. W. Innis, D. C. Smith, C. D. Lao, S. Y. Kim, J. S. Roberts, S. B. Gruber, K. J. Pienta, M. Talpaz, A. M. Chinnaiyan, Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
16. A. Martin, V. David, L. D. Quarles, Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92, 131-155 (2012).
17. S. Wöhrle, O. Bonny, N. Beluch, S. Gaulis, C. Stamm, M. Scheibler, M. Müller, B. Kinzel, A. Thuery, J. Brueggen, N. E. Hynes, W. R. Sellers, F. Hofmann, D. Graus-Porta, FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J. Bone Miner. Res. 26, 2486-2497 (2011).
18. K. B. Kim, J. Chesney, D. Robinson, H. Gardner, M. M. Shi, J. M. Kirkwood, Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin. Cancer Res. 17, 7451-7461 (2011).
19. E. Angevin, J. Lopez-Martin, C. C. Lin, J. E. Gschwend, A. Harzstark, D. Castellano, J. C. Soria, P. Sen, J. Chang, M. M. Shi, A. Kay, B. Escudier, Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin. Cancer Res. 19, 1257-1268 (2013).
20. E. S. Antonarakis, M. A. Carducci, Targeting angiogenesis for the treatment of prostate cancer. Expert Opin. Ther. Targets 16, 365-376 (2012).
21. M. Murakami, M. Simons, Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 15, 215-220 (2008).
22. J. P. O'Connor, A. Jackson, G. J. Parker, C. Roberts, G. C. Jayson, Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat. Rev. Clin. Oncol. 9, 167-177 (2012).
23. N. Murukesh, C. Dive, G. C. Jayson, Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8-18 (2010).
24. A. L. Jacob, C. Smith, J. Partanen, D. M. Ornitz, Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev. Biol. 296, 315-328 (2006).
25. O. Casanovas, D. J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
26. R. S. Kerbel, Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell 8, 269-271 (2005).
27. M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, M. R. Smith, Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 20, 913-920 (2009).
28. N.M. Navone, M. Olive, M. Ozen, R. Davis, P. Troncoso, S. M. Tu, D. Johnston, A. Pollack, S. Pathak, A. C. von Eschenbach, C. J. Logothetis, Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3, 2493-2500 (1997).
29. E. Efstathiou, M. Titus, D. Tsavachidou, V. Tzelepi, S. Wen, A. Hoang, A. Molina, N. Chieffo, L. A. Smith, M. Karlou, P. Troncoso, C. J. Logothetis, Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30, 637-643 (2012).
30. R. J. Lonigro, C. S. Grasso, D. R. Robinson, X. Jing, Y. M. Wu, X. Cao, M. J. Quist, S. A. Tomlins, K. J. Pienta, A. M. Chinnaiyan, Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 13, 1019-1025 (2011).
31. D. R. Robinson, Y. M. Wu, S. Kalyana-Sundaram, X. Cao, R. J. Lonigro, Y. S. Sung, C. L. Chen, L. Zhang, R. Wang, F. Su, M. K. Iyer, S. Roychowdhury, J. Siddiqui, K. J. Pienta, L. P. Kunju, M. Talpaz, J. M. Mosquera, S. Singer, S. M. Schuetze, C. R. Antonescu, A. M. Chinnaiyan, Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat. Genet. 45, 180-185 (2013).
32. B. Han, R. Mehra, S. M. Dhanasekaran, J. Yu, A. Menon, R. J. Lonigro, X. Wang, Y. Gong, L. Wang, S. Shankar, B. Laxman, R. B. Shah, S. Varambally, N. Palanisamy, S. A. Tomlins, C. Kumar-Sinha, A. M. Chinnaiyan, A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 68, 7629-7637 (2008).
33. D. Yang, L. Han, V. Kundra, Exogenous gene expression in tumors: Noninvasive quantification with functional and anatomic imaging in a mouse model. Radiology 235, 950-958 (2005).
34. P. Mathew, P. F. Thall, C. D. Bucana, W. K. Oh, M. J. Morris, D. M. Jones, M. M. Johnson, S. Wen, L. C. Pagliaro, N. M. Tannir, S. M. Tu, A. A. Meluch, L. Smith, L. Cohen, S. J. Kim, P. Troncoso, I. J. Fidler, C. J. Logothetis, Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin. Cancer Res. 13, 5816-5824 (2007).
35. E. Efstathiou, M. Titus, D. Tsavachidou, V. Tzelepi, S. Wen, A. Hoang, A. Molina, N. Chieffo, L. A. Smith, M. Karlou, P. Troncoso, C. J. Logothetis, Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30, 637-643 (2012).
36. A. J. Zurita, E. Jonasch, X. Wang, M. Khajavi, S. Yan, D. Z. Du, L. Xu, M. H. Herynk, S. McKee, H. T. Tran, C. J. Logothetis, N. M. Tannir, J. V. Heymach, A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 23, 46-52 (2012).